<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563221</url>
  </required_header>
  <id_info>
    <org_study_id>51982</org_study_id>
    <nct_id>NCT04563221</nct_id>
  </id_info>
  <brief_title>Prostatic Artery Embolization for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)</brief_title>
  <official_title>Prostatic Artery Embolization (PAE) Using LC Bead LUMI for the Treatment of Symptomatic Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andrew Picel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single center, prospective, investigational study to evaluate the safety and&#xD;
      efficacy of prostatic artery embolization (PAE) for the treatment of moderate to severe lower&#xD;
      urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH). Embolization will be&#xD;
      performed with LC Bead LUMI particles using a balloon occlusion microcatheter or standard&#xD;
      microcatheter.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding not approved&#xD;
  </why_stopped>
  <start_date type="Anticipated">May 1, 2022</start_date>
  <completion_date type="Anticipated">December 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with treatment related adverse events assessed by CTCAE v4.0.</measure>
    <time_frame>12 months post PAE</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean change from baseline in symptom score using the IPSS scale at 6 months</measure>
    <time_frame>Baseline and 6 months post PAE</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in Qmax (maximum urinary flow)</measure>
    <time_frame>Baseline, 6 months and 12 months post PAE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in PVR (post void residual)</measure>
    <time_frame>Baseline, 6 months and 12 months post PAE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in prostate volume</measure>
    <time_frame>Baseline, 6 months and 12 months post PAE</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from baseline in IPSS to measure long-terms subjective outcome</measure>
    <time_frame>Baseline, 12 and 24 months post PAE</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Benign Prostatic Hyperplasia</condition>
  <condition>Lower Urinary Tract Symptoms</condition>
  <arm_group>
    <arm_group_label>Balloon occlusion microcatheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo the PAE procedure using LC Bead LUMI delivered through a balloon occlusion microcatheter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard microcatheter</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will undergo the PAE procedure using LC Bead LUMI delivered through a standard microcatheter.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Prostatic artery embolization</intervention_name>
    <description>Prostatic artery embolization is performed using LC Bead LUMI, which is the investigational device. The particles are administered to the prostatic arteries using either a balloon occlusion or standard microcatheter. Follow-up is performed at 1 month, 6 months, 12 months, and 24 months after intervention.</description>
    <arm_group_label>Balloon occlusion microcatheter</arm_group_label>
    <arm_group_label>Standard microcatheter</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 45 years and ≤ 85 years old&#xD;
&#xD;
          -  Prostate volume ≥ 40 mL and ≤ 300 mL&#xD;
&#xD;
          -  Diagnosis of BPH with moderate to severe lower urinary tract symptoms (LUTS)&#xD;
&#xD;
          -  Refractory or intolerant to medical management&#xD;
&#xD;
          -  Ineligibility for or refusal of surgical management&#xD;
&#xD;
          -  No evidence of prostate cancer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of pelvic cancer&#xD;
&#xD;
          -  Neurogenic bladder disorder&#xD;
&#xD;
          -  Bladder diverticula greater than 5 cm or bladder stones&#xD;
&#xD;
          -  Acute urinary retention with Foley catheter dependence&#xD;
&#xD;
          -  Active urinary tract infection, interstitial cystitis, or prostatitis within the last&#xD;
             3 months&#xD;
&#xD;
          -  Prior surgical prostate intervention&#xD;
&#xD;
          -  Active participation in another clinical trial&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrew Picel, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 20, 2020</study_first_submitted>
  <study_first_submitted_qc>September 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Andrew Picel</investigator_full_name>
    <investigator_title>Assistant Clinical Professor</investigator_title>
  </responsible_party>
  <keyword>Benign prostatic hyperplasia (BPH)</keyword>
  <keyword>Prostatic artery embolization (PAE)</keyword>
  <keyword>Lower urinary tract symptoms (LUTS)</keyword>
  <keyword>Prostate artery embolization</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Hyperplasia</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Lower Urinary Tract Symptoms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

